Bao Van Tran

Dr. Bao Van Tran

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2026 in JHEP Reports
Verified
Journal Article
Open access
PDPham Minh Duc
Pham Minh Duc
LTLe Thi Thanh Thuy
Le Thi Thanh Thuy
HHHoang Hai
Hoang Hai
BTBao Van Tran
Bao Van Tran
NHNguyen Thi Ha
Nguyen Thi Ha
NKNorifumi Kawada
Norifumi Kawada
Single-cell fixed RNA profiling (FLEX) is a novel technique that captures RNA expression in frozen tissues at a single-cell resolution. We applied FLEX to mouse model of liver fibrosis progression and regression to identify novel antifibrotic targets. Mice were administered intraperitoneal thioacetamide for 10 weeks to induce fibrosis, regression was assessed 2 weeks after cessation. The livers were fixed, dissociated, and analysed using FLEX. Molecular validation included immunoblotting, immunohistochemistry, gene silencing/overexpression, cytokine/phosphokinase arrays, and human liver samples. Approximately 40,000 liver cells were profiled, integrated, and annotated into 10 major cell types using lineage-specific markers. Pericentral signature restoration in hepatocytes, scar-resolving genes (Mmp14 and Ctsl), fenestrae restoration in liver sinusoidal endothelial cells, anti-inflammatory Kupffer cells, reduced fibrogenic cholangiocytes, and recovery-associated immune cell subsets were observed. During fibrosis, monocyte-derived macrophages secrete semaphorin-4D (SEMA4D), which binds to Plexin B2 on hepatic stellate cells (HSCs). SEMA4D+ cells were upregulated in mouse fibrotic livers (n = 6, p <0.05). Recombinant SEMA4D induces type I collagen in HSCs, whereas humanised monoclonal IgG4 SEMA4D blockade (VX15/2503) attenuates fibrosis in vivo (n = 5, p <0.05). LIM and cysteine-rich domains 1 (LMCD1) was enriched in fibrotic HSCs and suppressed during regression. LMCD1 knockdown reduced the expression of fibrotic protein, while LMCD1 overexpression promoted the expression of fibrotic protein via AKT/mTOR signalling. LMCD1 and SEMA4D are localised in the fibrotic septa and are correlated with the fibrotic stage of MASLD (n = 34, p <0.05) and HCV (n = 76, p <0.05) in humans. This FLEX-based single-cell atlas revealed critical transcriptional programs and cell-cell interactions, identifying SEMA4D and LMCD1 as promising therapeutic targets for liver fibrosis. In this study, we applied a novel technique, single-cell fixed RNA profiling, to profile 38,136 cells obtained from control, thioacetamide-induced liver fibrosis, and regression-phase mouse livers, generating a high-resolution atlas of liver fibrosis progression and regression. We identified the transcriptomic patterns of regressed cell subpopulations and uncovered two key therapeutic targets: the macrophage-derived factor semaphorin-4D (SEMA4D) and the hepatic stellate cell-specific transcription factor LIM and cysteine-rich domains 1 (LMCD1). Treatment with a humanised monoclonal IgG4 antibody against SEMA4D significantly alleviated liver fibrosis in the thioacetamide-induced mouse model. SEMA4D and LMCD1 expression correlated with the metabolic dysfunction-associated steatotic liver disease-related fibrosis stage, and the attenuation of SEMA4D and LMCD1 after HCV-sustained virologic response reduced the risk of progression to hepatocellular carcinoma.

14 April 2026 in Antioxidants
Verified
Journal Article
Open access
PDF file
LTLe Thi Thanh Thuy
Le Thi Thanh Thuy
HHHoang Hai
Hoang Hai
APAnh Tuan Pham
Anh Tuan Pham
Nguyen Bui Tam ChiNguyen Bui Tam Chi
Nguyen Bui Tam Chi
BTBao Van Tran
Bao Van Tran
MHMichelle Hermiston
Michelle Hermiston
Chronic liver diseases, including fibrosis and hepatocellular carcinoma (HCC), are primarily driven by oxidative stress, yet traditional antioxidant therapies often lack the specificity and efficacy required for clinical success. This review evaluates the emerging therapeutic potential of two atypical globins, cytoglobin (CYGB) and neuroglobin (NGB), exploring their unique hexacoordinated heme structures that enable potent reactive oxygen and nitrogen species (ROS/RNS) scavenging and redox-regulated signaling. We summarize a broad range of in vitro and in vivo evidence demonstrating that these globins deactivate hepatic stellate cells, reduce extracellular matrix accumulation, and function as tumor suppressors by modulating pathways such as Raf/MEK/ERK and NRF2. In human cohorts, CYGB expression levels inversely correlate with the progression of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and HCC, highlighting its potential as a clinical biomarker. Furthermore, recombinant protein therapies involving CYGB and NGB show promise in promoting collagen degradation and inhibiting malignant transformation. We conclude that CYGB and NGB represent sophisticated catalytic redox regulators that offer a novel therapeutic paradigm for restoring redox homeostasis. While delivery and pharmacokinetic barriers remain, these globins are highly promising candidates for first-in-class biologics in hepatology.

30 April 2026 in Tạp chí Y Dược Huế
Verified
Journal Article
Open access
VNVan Mao Nguyen
Van Mao Nguyen
BTBao Van Tran
Bao Van Tran
TTThi Nam Phuong Tran
Thi Nam Phuong Tran
NTNam Dong Tran
Nam Dong Tran
Background: Soft tissue tumors represent a relatively common and heterogeneous group of lesions characterized by diverse yet nonspecific clinical manifestations. Although histopathology remains the diagnostic gold standard, the application of advanced techniques such as immunohistochemistry is indispensable to ensure the accurate diagnosis with the latest WHO classification. Objectives: (1) To describe clinical characteristics and the histopathological classification of soft tissue tumors. (2) To evaluate the expression of immunohistochemical markers in soft tissue tumors. Materials and methods: A cross-sectional study was conducted on 166 patients diagnosed with soft tissue t umors between 04/2025 and 01/2026 at Hue University of Medicine and Pharmacy Hospital. Results: Malignant soft tissue tumors accounted for 21.1% of cases. The majority presented with a single lesion (91.6%), most commonly located in the superficial trunk (34.4%). Tumors smaller than 5 cm comprised 68.1% of cases. Adipocytic tumors were the most frequent (42.8%). Lipoma and hemangioma were predominant in the benign group (53,4% and 15,5%), fibrohistiocytoma in the borderline group (61,5%), and fibrosarcoma in the malignant group (22,7%). Immunohistochemistry revealed the expression of characteristic markers that supported the diagnostic classification, Vimentine (+) 100%, Desmine (+) 5/5 cases and SMA (+) 3/5 cases for smooth tumours, CD68 (+) 100% for fibrohistiocytic tumours, CD34 (+) for vascular and the other tumours.. Conclusion: Malignant soft tissue tumors accounted for 21.1% of cases. Besides histopathology, immunohistochemistry revealed the expression of characteristic markers that supported the key role for the classification of tumour types. Keywords: soft tissue tumours, histopathology, clinical characteristics, immunohistochemistry

23 May 2026 in Cancers
Verified
Journal Article
Open access
PDF file
NSNguyen Tran Quang Sang
Nguyen Tran Quang Sang
NKNguyen Van Khanh
Nguyen Van Khanh
HHHoang Hai
Hoang Hai
DTDung Trung Tran
Dung Trung Tran
Tran Duc ThanhTran Duc Thanh
Tran Duc Thanh
LTLe Thi Thanh Thuy
Le Thi Thanh Thuy
Background: Osteosarcoma remains the most common primary malignant bone tumor in children and adolescents, with largely unchanged survival outcomes in recent decades. Non-invasive biomarkers for preoperative risk stratification are urgently needed. Circulating immune checkpoint proteins (ICPs) and bone remodeling factors (BRFs) represent promising candidates; however, their combined prognostic value in osteosarcoma remains unclear. Methods: We prospectively analyzed plasma samples from 47 patients with osteosarcoma, selecting the earliest available sample before disease progression or the last follow-up. A panel of ICPs and BRFs was quantified using multiplex immunoassays. sHVEM and sCD27 were used to construct a two-marker ICP signature (ICP2); subtypes were defined by unsupervised consensus clustering (k = 2) applied to log2-transformed sHVEM and sCD27 concentrations, and sOPN was included for integrative analysis. Survival associations were assessed using Kaplan–Meier analysis and Firth’s penalized Cox regression. The model performance was evaluated using Harrell’s C-index. Results: Two ICP2 subtypes were identified (type1, n = 26; type2, n = 21). ICP2-type2 was associated with significantly worse progression free survival (PFS) (p = 0.0045) and overall survival (OS) (p = 0.0024) and remained an independent predictor after adjusting clinicopathological factors. The ICP2 model demonstrated high discriminative performance (C-index 0.924 for PFS and 0.903 for OS). Internal validation by leave-one-out cross-validation (LOOCV), in which consensus clustering was re-derived at each fold, yielded corrected C-indices of 0.612 for PFS and 0.806 for OS (versus apparent estimates of 0.687 and 0.689, respectively), confirming acceptable-to-good discrimination after accounting for overfitting. Elevated sOPN was associated with poorer survival in the exploratory analyses, although its prognostic value was less consistent under a pre-specified cutoff. In the combined models, sOPN provided modest additional value for OS stratification, with the grdgfdgICP2-type2/OPN-high subgroup exhibiting the poorest outcome. Conclusions: The circulating sHVEM/sCD27 signature defines prognostically distinct osteosarcoma subtypes with a strong discriminative performance. This minimally invasive model may support preoperative risk stratification. Integration with sOPN suggests a potential biological link between immune regulation and bone remodeling, warranting validation in larger cohorts.